Jiangsu Hengrui Pharma 
Welcome,         Profile    Billing    Logout  
 196 Products   52 Diseases   196 Products   3529 Trials   15381 News 


«12...173174175176177178179180181182183...208209»
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Enrollment closed, Trial primary completion date, Real-world evidence, Real-world:  The Real World Study of Apatinib for Gastric Cancer Treatment in Henan Province (clinicaltrials.gov) -  May 27, 2020   
    P=N/A,  N=1000, Active, not recruiting, 
    Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2020 --> Aug 2020
  • ||||||||||  AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
    Enrollment open:  A Phase II Study in Patients With Alopecia Areata (clinicaltrials.gov) -  May 26, 2020   
    P2,  N=80, Recruiting, 
    Registered 23 June 2016. Active, not recruiting --> Recruiting
  • ||||||||||  SHR0410 / Jiangsu Hengrui Pharma
    Enrollment open:  A Study of SHR0410 in Hemodialysis Patients With Pruritus (clinicaltrials.gov) -  May 22, 2020   
    P1,  N=54, Recruiting, 
    Adverse events with apatinib need to be monitored during application, despite the manageable appearance. Not yet recruiting --> Recruiting
  • ||||||||||  arketamine nasal spray (HR071603) / Jiangsu Hengrui Pharma
    Enrollment open, Trial completion date, Trial primary completion date:  A Study of HR071603(Ketamine Nasal Spray) in Healthy Subjects (clinicaltrials.gov) -  May 22, 2020   
    P1,  N=40, Recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial completion date: Mar 2020 --> Aug 2020 | Trial primary completion date: Feb 2020 --> Jul 2020
  • ||||||||||  SHR0410 / Jiangsu Hengrui Pharma
    Enrollment closed, Trial completion date, Trial primary completion date:  A Study of SHR4010 in Patients With Hemodialysis (clinicaltrials.gov) -  May 22, 2020   
    P1,  N=12, Active, not recruiting, 
    Not yet recruiting --> Recruiting | Trial completion date: Mar 2020 --> Aug 2020 | Trial primary completion date: Feb 2020 --> Jul 2020 Recruiting --> Active, not recruiting | Trial completion date: Nov 2019 --> May 2020 | Trial primary completion date: Sep 2019 --> Apr 2020
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Journal:  Pretreatment PET/CT imaging of angiogenesis based on F-RGD tracer uptake may predict antiangiogenic response. (Pubmed Central) -  May 20, 2020   
    In conclusion, apatinib combined with TACE revealed certain survival benefits for HCC patients who experienced progression following TACE, which can provide a promising strategy for HCC treatment. F-RGD uptake on PET/CT imaging pretreatment may predict the response to antiangiogenic therapy, with higher F-RGD uptake in tumors predicting a better response to apatinib therapy.
  • ||||||||||  AiRuiKa (camrelizumab) / Incyte
    Journal, Checkpoint inhibition:  Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: beyond an era of chemoradiation? (Pubmed Central) -  May 19, 2020   
    Within the observed groups, camrelizumab combined with chemotherapy achieved an objective response in 91% of patients as first-line treatment for metastatic NPC (PFS 68% at 1-year) but this was associated with a high rate of grade >3 adverse events (87%; CTCAE version 4.03)...In considering checkpoint immunotherapies for NPC, initial results show promise for anti-PD1 interventions. Further phase I-III trials are in progress to clarify clinical outcomes, fully determine safety profiles, and optimize drug combinations and administration schedules.
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Enrollment change, Trial withdrawal, Metastases:  Apatinib for Advanced Soft Tissue Sarcoma Patients: a Phase 2, Multicenter Trial (clinicaltrials.gov) -  May 19, 2020   
    P2,  N=0, Withdrawn, 
    Further phase I-III trials are in progress to clarify clinical outcomes, fully determine safety profiles, and optimize drug combinations and administration schedules. N=30 --> 0 | Completed --> Withdrawn
  • ||||||||||  Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer (clinicaltrials.gov) -  May 18, 2020   
    P2,  N=12, Terminated, 
    N=80 --> 0 | Recruiting --> Withdrawn N=258 --> 12 | Trial completion date: May 2028 --> Apr 2020 | Recruiting --> Terminated | Trial primary completion date: Aug 2022 --> Apr 2020; We terminated this trial and initiated a new one including pertuzumab.
  • ||||||||||  AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
    Enrollment closed:  A Phase II Study in Patients With Alopecia Areata (clinicaltrials.gov) -  May 18, 2020   
    P2,  N=80, Active, not recruiting, 
    N=258 --> 12 | Trial completion date: May 2028 --> Apr 2020 | Recruiting --> Terminated | Trial primary completion date: Aug 2022 --> Apr 2020; We terminated this trial and initiated a new one including pertuzumab. Not yet recruiting --> Active, not recruiting
  • ||||||||||  TG-1701, a novel irreversible Bruton’s kinase (BTK) inhibitor, cooperates with ublituximab-driven ADCC and ADCP in in vitro and in vivo models of ibrutinib-resistant mantle cell lymphoma (Virtual Meeting II: E-Posters) -  May 16, 2020 - Abstract #AACRII2020AACR-II_682;    
    We then evaluated the activity of TG-1701 and ibrutinib on anti-CD20 antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP), as ibrutinib has previously been show to block rituximab-mediated ADCC due to off-target inhibition of ITK (Kohrt et al., Blood 2014)...In accordance with in vitro data, the antitumor activity of the drug combination was associated with increased production of IL-2, IL-6 and TNFα, and with an increased infiltration of mouse macrophages and NK cells. Altogether, these data warrant further clinical investigation of TG-1701-mediated engagement of TME-related anti-tumor effect, and clinical evaluation of the triple combination of TG-1701, ublituximab, and umbralisib, is ongoing.
  • ||||||||||  remimazolam tosylate (HR-7056) / Jiangsu Hengrui Pharma
    Trial completion, Enrollment change, Trial primary completion date, Surgery:  A Clinical Study of Remimazolam Tosilate Compared to Propofol for General Anesthesia During Elective Surgery (clinicaltrials.gov) -  May 15, 2020   
    P3,  N=330, Completed, 
    This study (NCT03671590) has opened enrollment in disease-specific cohorts. Recruiting --> Completed | N=498 --> 330 | Trial primary completion date: Sep 2019 --> Dec 2019
  • ||||||||||  AiRuiEn (rezvilutamide) / Jiangsu Hengrui Pharma, AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
    Enrollment closed:  A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC (clinicaltrials.gov) -  May 13, 2020   
    P2,  N=144, Active, not recruiting, 
    Recruiting --> Completed | N=498 --> 330 | Trial primary completion date: Sep 2019 --> Dec 2019 Recruiting --> Active, not recruiting
  • ||||||||||  AiRuiEn (rezvilutamide) / Jiangsu Hengrui Pharma
    Enrollment closed, Trial completion date, Trial primary completion date:  A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients (clinicaltrials.gov) -  May 13, 2020   
    P1/2,  N=197, Active, not recruiting, 
    Funding The study was supported by Jiangxi provincial department of science and technology [grant number 2015BAB215007 and 2016BAB205264]. Recruiting --> Active, not recruiting | Trial completion date: Jun 2020 --> Jun 2021 | Trial primary completion date: Dec 2019 --> Dec 2020
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Biomarker, Trial completion date, Trial primary completion date, Adverse drug reaction, Metastases:  Study on the Adverse Drug Reactions (ADRs) of Apatinib and Their Biomarker Correlations (clinicaltrials.gov) -  May 11, 2020   
    P4,  N=217, Recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Jun 2020 --> Jun 2021 | Trial primary completion date: Dec 2019 --> Dec 2020 Trial completion date: Dec 2019 --> Dec 2021 | Trial primary completion date: Dec 2019 --> Dec 2020
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Enrollment closed, Enrollment change, Trial primary completion date:  Study of Apatinib in Patients With Differentiated Thyroid Cancer (clinicaltrials.gov) -  May 8, 2020   
    P2,  N=20, Active, not recruiting, 
    Trial completion date: Dec 2019 --> Dec 2021 | Trial primary completion date: Dec 2019 --> Dec 2020 Recruiting --> Active, not recruiting | N=10 --> 20 | Trial primary completion date: Dec 2016 --> Feb 2020
  • ||||||||||  plinabulin (BPI 2358) / BeyondSpring
    Trial completion date, Trial primary completion date:  PROTECTIVE-2: Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia (clinicaltrials.gov) -  May 7, 2020   
    P3,  N=222, Recruiting, 
    Recruiting --> Active, not recruiting | N=10 --> 20 | Trial primary completion date: Dec 2016 --> Feb 2020 Trial completion date: Apr 2020 --> Jul 2020 | Trial primary completion date: Mar 2020 --> Jun 2020